ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

被引：265

作者：

Hicks, Rodney J. ^{[1
]}

Kwekkeboom, Dik J. ^{[2
]}

Krenning, Eric ^{[3
]}

Bodei, Lisa ^{[4
]}

Grozinsky-Glasberg, Simona ^{[5
]}

Arnold, Rudolf

Borbath, Ivan ^{[6
]}

Cwikla, Jaroslaw ^{[7
]}

Toumpanakis, Christos ^{[8
]}

Kaltsas, Greg ^{[9
]}

Davies, Philippa ^{[8
]}

Hoersch, Dieter ^{[10
]}

Tiensuu Janson, Eva ^{[11
]}

Ramage, John ^{[12
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Imaging & Neuroendocrine Serv, 305 Grattan St, Melbourne, Vic 3000, Australia

[2] Erasmus MC, ENETS Ctr Excellence Rotterdam, Div Nucl Med, Dept Internal Med, Rotterdam, Netherlands

[3] Erasmus MC, Cyclotron Rotterdam BV, Rotterdam, Netherlands

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Hadassah Hebrew Univ, Med Ctr, Neuroendocrine Tumor Unit, Endocrinol & Metab Serv,Dept Med, Jerusalem, Israel

[6] Clin Univ St Luc, Serv Gastroenterol, Brussels, Belgium

[7] Univ Warmia & Mazury, Dept Radiol, Fac Med Sci, Olsztyn, Poland

[8] Royal Free Hosp, Neuroendocrine Tumour Unit, London, England

[9] Natl Univ Athens, Div Endocrinol, Dept Pathophysiol, Athens, Greece

[10] Gastroenterol & Endocrinol Ctr Neuroendocrine Tum, Bad Berka, Germany

[11] Uppsala Univ Hosp, Dept Endocrine Oncol, Uppsala, Sweden

[12] Hampshire Hosp NHS Trust, Gastroenterol Dept, Basingstoke, Hants, England

来源：

NEUROENDOCRINOLOGY | 2017年 / 105卷 / 03期

关键词：

Radiolabelled somatostatin analogues; Gastroenteropancreatic neuroendocrine tumour; Neuroendocrine tumour; Peptide receptor radionuclide therapy; CHEMORADIONUCLIDE THERAPY; PHASE-I; RADIOPEPTIDE LU-177-OCTREOTATE; TYR(3) OCTREOTATE; LIVER METASTASES; PREDICTIVE-VALUE; F-18-FDG PET; TUMORS; SURVIVAL; Y-90;

D O I：

10.1159/000475526

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish Lu-177-DOTA-octreotate (LutaThera (R)) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies. (C) 2017 S. Karger AG, Basel

引用

页码：295 / 309

页数：15

共 93 条

[1] Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies [J].

Anthony, LB ;

Woltering, EA ;

Espenan, GD ;

Cronin, MD ;

Maloney, TJ ;

McCarthy, KE .

SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) :123-132

[2] High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuro endocrine Tumors: A Long-Term Evaluation [J].

Bahri, Haifa ;

Laurence, Lenoir ;

Edeine, Julien ;

Leghzali, Houda ;

Devillers, Anne ;

Raoul, Jean-Luc ;

Cuggia, Marc ;

Mesbah, Habiba ;

Clement, Bruno ;

Boucher, Eveline ;

Garin, Etienne .

JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (11) :1786-1790

[3] The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable [J].

Barber, T. W. ;

Hofman, M. S. ;

Thomson, B. N. J. ;

Hicks, R. J. .

EJSO, 2012, 38 (01) :64-71

[4] [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study [J].

Baum, Richard P. ;

Kluge, Andreas W. ;

Kulkarni, Harshad ;

Schorr-Neufing, Ulrike ;

Niepsch, Karin ;

Bitterlich, Norman ;

van Echteld, Cees J. A. .

THERANOSTICS, 2016, 6 (04) :501-510

[5] Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Carreras, Cecilia .

SEMINARS IN NUCLEAR MEDICINE, 2012, 42 (03) :190-207

[6] Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system [J].

Beauregard, Jean-Mathieu ;

Hofman, Michael S. ;

Pereira, Jucilene M. ;

Eu, Peter ;

Hicks, Rodney J. .

CANCER IMAGING, 2011, 11 (01) :56-66

[7] 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors [J].

Binderup, Tina ;

Knigge, Ulrich ;

Loft, Annika ;

Federspiel, Birgitte ;

Kjaer, Andreas .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :978-985

[8] Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study [J].

Bodei, L ;

Cremonesi, M ;

Zoboli, S ;

Grana, C ;

Bartolomei, M ;

Rocca, P ;

Caracciolo, M ;

Mäcke, HR ;

Chinol, M ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) :207-216

[9] Myeloid neoplasms after chemotherapy and PRRT: myth and reality [J].

Bodei, Lisa ;

Modlin, Irvin M. ;

Luster, Markus ;

Forrer, Flavio ;

Cremonesi, Marta ;

Hicks, Rodney J. ;

Ezziddin, Samer ;

Kidd, Mark ;

Chiti, Arturo .

[10] Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors [J].

Bodei, Lisa ;

Kidd, Mark ;

Paganelli, Giovanni ;

Grana, Chiara M. ;

Drozdov, Ignat ;

Cremonesi, Marta ;

Lepensky, Christopher ;

Kwekkeboom, Dik J. ;

Baum, Richard P. ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) :5-19

← 1 2 3 4 5 6 7 8 9 10 →